While prostate-specific antigen (PSA)-based screening for PCa has had a beneficial effect in reducing PCa mortality, it has also resulted in the problem of overdiagnosis, overtreatment, and a substantial number of unnecessary biopsies (Srivastava et al. 2019). Here, KLK3 is linked to posterior cortical atrophy.